The National Alkaptonuria Centre 


Many people diagnosed with alkaptonuria (AKU), have difficulty accessing efficient and effective care to treat their AKU. For some, there has been a lack of local expertise and knowledge when dealing with such a rare disease, resulting in the failure to detect complications of AKU and an inability to make appropriate treatments available.

The Robert Gregory National Alkaptonuria Centre exists to change this. It is needed to ensure that everyone with AKU has access to a knowledgeable team of specialists who can manage their care efficiently. 

The National AKU Centre was established by the Department of Health (National Specialised Services Commissioning Group) and opened to patients on 18th June 2012. The service was set up to provide assessments and treatment for people with AKU and is based at The Royal Liverpool University Hospital. It is a free NHS service open to anyone over the age of 16 who has been diagnosed with AKU and living in England or Scotland.

Patients who attend the National AKU Centre will receive: 

  • A full health assessment and treatment of AKU
  • Access to the drug nitisinone
  • Advice on living with and managing the disease.

Referral to The National AKU Centre

Once a diagnosis of AKU has been confirmed a GP or other relevant medical professional can make a referral to the National Centre. Diagnosis is confirmed by measuring the homogentisic acid levels in a blood or urine test. The referral is assessed by the team in Liverpool and the person is then invited to attend the National Centre.

The National AKU Centre can accommodate up to five patients per month and anyone attending is expected to return for review on an annual basis at the same time each year. The average stay at the Centre is three to four days.

Referrals from Wales

Wales has its own referral process for accessing the NAC. In the first instance, a GP or relevant physician must follow the appropriate clinical gateway. For AKU, a person has to be referred to the Clinical Gatekeeper based at Cardiff University Hospital. He will determine whether the specialist services needed to meet an individual’s needs is available in Wales. If it is deemed that such services are not available a referral to the NAC is agreed and the Gatekeeper will apply to the Welsh Health Specialised Services Committee for funding. If funding is agreed, the Gatekeeper can make a direct referral to the NAC.

Nitisinone is a drug currently licensed for another rare disease and it is thought to be effective in treating patients with AKU. All English and Scottish patients who attend the National AKU Centre are given access to nitisinone. At this time funding for patients in Wales and Northern Ireland is not available for accessing nitisinone.

If you would like to know more about the National Alkaptonuria Centre, please contact Lesley Harrison by emailing her at [email protected] or giving her a call on 07586759028. 

Published: 24.07.16 Next Review Date: 24.07.19


AKU Twitter

AKU Blog

Children's Workshop 2017 Preview

On 26th July we are excited to be holding our first ever Children’s Workshop. This ev.. ...more

A big thank you to Pedwar Pawen Dog Training Club!

Support often comes from unlikely places, but it is safe to say we never expected to receive.. ...more

Presenting National AKU Centre Research at an International Conference

This week’s blog comes from the team at Costello Medical ( ...more

EURORDIS Membership Meeting 2017, Budapest

On the 19th- 20th May, Oliver and Ciarán travelled to Budapest to represent the AKU Socie.. ...more

RCN Congress 2017

The Royal College of Nursing Congress is held each year to bring together over 4,000 nur.. ...more